The study explaining that the threat of the antibiotic resistant strains of infection is an escalating global health concern; and improving targeting of antibiotics is crucial in reducing the spread of resistance. But current susceptibility testing methods typically take two to three days to arrive back with a GP from hospital laboratories because they rely on detecting bacterial growth.
As UTIs are one of the most common reasons that antibiotics are prescribing; so that the potential contribution this is causing to antibiotic resistance might be very significant. In addition, many patients may be making things worse by taking leftover antibiotics; that they have been prescribing and using them to treat other infections, or by not finishing their course of treatment.
But a new rapid patient test that could identify; whether bacteria isolating from clinical samples are antibiotic resistant in under two hours is being trialling on a range of antibiotics commonly using to treat urinary tract infections (UTIs). If successful, the test could transform decision-making around antibiotic choice by helping inform; the five million antibiotic prescriptions written each year in the UK for UTIs.
Antibiotic resistant strains
The rapid antimicrobial susceptibility test (AST), uses novel optical technology to see inside bacteria cells and detect tiny movements indicating whether the cells are alive or not and could be antibiotic resistant. Based on technology developed at Bristol’s School of Physics, the test is being trialled using bacteria derived from human UTI samples on a range of antibiotics commonly used to treat them.
Bacteria treated with an effective antibiotic will show alterations in these movements; after only a few minutes, meaning that we very quickly tell whether an antibiotic is suitable for prescribing to an individual patient. The exciting news is that we have produced promising results for a range of antibiotics commonly used to treat urinary infections.
Testing to bacteria
But extend this testing to bacteria in other samples such as blood where sepsis is a real threat to life. Vitamica has now announced a bid to raise further funding to continue development of this pioneering antimicrobial susceptibility test; and is seeking to raise a further £1.5 million to extend the program of research over the next two years.
But however, the study finding that the infections considering under the antibacterial infection; non-executive chairman of Vitamica, added. Vitamica’s progress since last year has been very promising. Completing our next investment round by the end of 2019; will ensure we maintain momentum and can move confidently towards our next strategic milestones.